Yulia Slavina

Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026

Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026
Upstream Bio trial data at ATS2026

Upstream Bio, Inc. presented two new posters from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at ATS2026.

The data, which included findings on patients with comorbid asthma, was shared during the conference on Monday, offering new insights into therapeutic response for this challenging patient population. Posters P1397 and P1398 provided detailed results on the investigational antibody therapy in an area of high unmet need.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.